Institutional investors hold a majority ownership of IMGN through the 84.46% of the outstanding shares that they control. This interest is also higher than at almost any other company in the Biotechnology industry. Last, during the quarter ended December 2014, these large investors purchased a net $8.0 million shares.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
CLEARBRIDGE INVESTMENTS LLC Bought 2.1 Million shares of ImmunoGen Inc
MEDICAL STRATEGY GMBH Bought 92.0 Thousand shares of ImmunoGen Inc
BAXTER BROS., INC. Bought 18.7 Thousand shares of ImmunoGen Inc